Podcasts

Episode 69: Parkinson’s Foundation Center of Excellence: What Does it Take and What Does it Mean?

Since the early 2000’s, centers of excellence for various diseases or procedures have become common. These are specialized programs within healthcare institutions that bring together experts and resources to target different aspects of the disease or condition to give patients a unified resource for addressing their needs in a comprehensive manner. Besides optimizing resources for patients, the centers of excellence provide advantages for healthcare providers by integrating experts and resources to draw upon within one organization.

Much work goes into assembling and being designated a Parkinson’s Foundation Center of Excellence. At this point, the Parkinson’s Foundation has recognized 47 CoE’s – 34 in the United States and 14 international. Not only do they have to have clinical expertise, but part of their mandate is to do research, education, and community outreach to underserved communities that otherwise could not access the CoE or find appropriate care within their own locales.

In this episode Clarissa Martinez-Rubio, Senior Director of Clinical Affairs of the Parkinson’s Foundation, describes what these centers are and the criteria for earning a designation as a CoE. Then Joe Salvatore talks about his mother’s experience getting a second opinion at a Parkinson’s Foundation CoE and how it helped change the course of her disease.

Released: December 3, 2019

Videos & Webinars

Medicare & Parkinson’s: Your Frequently Asked Questions

Almost 90% of people with Parkinson’s disease (PD) are covered by Medicare. We know that navigating Medicare and understanding what it means for managing your Parkinson’s disease can be overwhelming. In part two of our Medicare and Parkinson’s webinar series, we will drill down into some of the most frequently asked questions about Medicare coverage like: Are there annual caps on physical, occupational and speech therapy?; What types of mental health treatment are covered under Medicare?; and Will Medicare pay for long term care services?

Download Slides

Presenters

Jessica Shurer, MSW, LCSW
Director of Patient and Carepartner Advocacy, CurePSP

Carrie Blakeway Amero, MPA
Director for Long-Term Services and Supports, AARP

Adolfo Diaz
Associate Vice President of Information & Resources, Parkinson's Foundation

Podcasts

Episode 68: The Role of the Microbiome in PD: Part One

How and why Parkinson’s disease (PD) starts and progresses is still not exactly known, but active research points to genetics and environment, among other factors. The environment is both external and internal – external in terms of what people encounter outside their bodies and internal in terms of what is inside their bodies. Researchers studying a variety of diseases have learned the importance of the microbiome in health and disease. The microbiome consists of all those bacteria, fungi, and viruses that occupy niches on and inside of people, such as on the skin, in the nose and mouth, and in the gut. These organisms can have far reaching effects in the body, distant from their own locations. Some of these interactions can affect the brain.

Ali Keshavarzian, MD, Chief of the Division of Digestive Diseases and Nutrition at Rush University in Chicago has been studying the role of the gut microbiome and its relation to inflammation, such as in inflammatory bowel disease, in addition to more distant sites including in the brain. His research includes the role of the gut microbiome as a contributing factor to the development and progression of PD as well as the potential to manipulate it to help manage the disease. He conducts both basic science research using animal models and clinical research with people with PD.

Released: November 19, 2019

Audiobooks

Sleep: A Mind Guide to Parkinson's Disease

Consider this your practical guide for achieving good sleep health. This book addresses healthy sleep, sleep changes due to aging and sleep problems due to Parkinson’s, as well as diagnosis, treatment and coping strategies.

LISTEN NOW

Raise Awareness

PD Dementia: An Important Conversation

Nurse resting her hand on the shoulder of her patient

Many people with Parkinson’s disease (PD) experience some degree of cognitive change, such as slowness of memory, changes in thinking, trouble focusing or difficulty finding words. Dementia is a permanent cognitive change that interferes with daily activities and quality of life. Identifying thinking changes early and discussing them with your doctor are the first steps in treating or ruling out PD-related dementia.

This article is based on a Parkinson’s Foundation Expert Briefing Let’s Talk About Dementia presented by Dr. James Leverenz, Director, Lou Ruvo Center for Brain Health at Cleveland Clinic, a Parkinson’s Foundation Center of Excellence.

Slowed movement, tremor and stiffness are some of the visible movement signs of Parkinson's disease. Though not visible, the impact of non-movement symptoms can be even more challenging for people with PD and their loved ones — this includes issues with thinking and memory. While PD-related cognitive change can be mild, between 60 to 80% of people living with PD for 15 years or more can experience disease-related dementia. Awareness of thinking changes can ensure early treatment.

Lewy Body Dementias

In Parkinson’s, the protein alpha-synuclein misfolds and forms clusters in the brain called Lewy bodies. These sticky clusters upset normal brain function. Lewy bodies are strongly linked to PD and dementia.

Nearly 1.5 million Americans are impacted by Lewy body dementias, including those living with:

  • Parkinson’s disease dementia (PDD): diagnosed when significant cognitive decline occurs in someone living with Parkinson’s movement symptoms for a year or more (usually several years).
  • Dementia with Lewy bodies (DLB): diagnosed when cognitive decline occurs before or at the same time as motor symptoms.

Almost 50% of people with Alzheimer's disease also have some Lewy body brain abnormalities. These are frequently seen in both people who live with sporadic and familial forms of Alzheimer's. When these changes go beyond a part of the brain called the amygdala, people often have some of the same symptoms as people living with dementia with Lewy bodies , frequently developing Parkinson's-like motor symptoms. This is known as the Lewy body variant of Alzheimer disease.

Some researchers theorize that Alzheimer's disease may drive clumping of Lewy bodies. New therapies designed to slow Alzheimer's progression could also hold possibility to slow Lewy body development — another reason for the importance of an early and correct diagnosis, and early treatment.

Dementia Signs and Symptoms

In addition to memory, thinking and behavior changes, other symptoms include:

Despite many shared symptoms across Lewy body dementia diseases, people often store and recall information differently, depending on which cognitive disorder they are living with.

Adding and retaining new memories is often difficult for people living with Alzheimer's disease. It may be challenging for someone with Alzheimer's to remember a question or conversation just minutes after, or they may have forgotten events from the previous day. Encoding new information can be an issue. However, if a person experiencing PD thinking changes struggles retrieving a memory, they can often pull it up with a clue or a reminder.

This means people with PD dementia can store memories. Rather than primary encoding difficulty, they often experience retrieval challenges — an executive dysfunction similar to difficulty multitasking or staying on track during conversations.

People with Alzheimer’s disease tend to have less awareness that they are hallucinating. A person with PD dementia or dementia with Lewy bodies can more often recognize that they are experiencing hallucinations. It’s important for the care provider to ask the person experiencing changes “Do you see things?” People with PD-related dementia will often acknowledge that they do see things, are aware the hallucinations are not real and are not bothered by what they see.

Diagnosing Lewy Body Dementias

Ensuring the person living with thinking changes receives the correct diagnosis is important. When diagnosing dementia, a doctor, neurologist or other healthcare expert will look for the ability to retrieve retained memories, early executive dysfunction or multitasking difficulties.

A review of symptoms, medications, medical history and more are also key to an accurate diagnosis. Your doctor will also rule out other medical illnesses — urinary tract infections or pneumonia can be related to sudden confusion and agitation.

Work with your doctor to identify any medications that might impact symptoms. Some medicines can cause or worsen confusion and hallucinations, including:

  • Certain dopamine-boosting medications that ease movement at lower doses but may worsen thinking problems at higher doses
  • Old antipsychotics, such as haloperidol, and anticholinergic (acetylcholine-blocking)
  • Medications, such as trihexyphenydil, sometimes used to treat tremor

Therapies

Medications used in Alzheimer’s disease have benefits in PD dementia, including rivastigmine, donepezil and galantamine. Selective serotonin reuptake inhibitors (SSRIs), used for depression, may also be beneficial.

For people with Parkinson’s experiencing rapid eye movement (REM) sleep behavior disorder, your doctor might recommend the over-the-counter sleep aid melatonin. Clonazepam is frequently used if melatonin is not effective, although it can cause confusion, daytime sleepiness and other side effects.

Cognitive remediation, provided by a neuropsychologist or speech-language pathologist, focuses on strengthening cognition.

Behavior management modifies activities and environments to improve abilities and independence. It includes creating a daily routine, decluttering living spaces, increasing lighting and using assistive tools to reduce confusion.

Exercise, physical activity and social connection can also benefit cognitive health.

On the Horizon

Research is currently underway to better understand dementia and discover disease-specific therapies. Diagnosing and treating the earliest stages of thinking change can ensure early lifestyle adjustments and the best chance for responsive therapy.

Understanding the biological differences behind the development and onset of all Lewy body dementias will be essential to future disease-specific therapies.

Scientists are currently working to standardize testing of blood and body fluids to reveal amassed Lewy body alpha-synuclein. This could serve as an early detection tool for neurodegenerative disorders related to the protein, such as PD.

Biomarkers for the Lewy Body Dementias, a National Institutes of Health-funded study, recently awarded more than $10 million to the Cleveland Clinic to expand the national Dementia with Lewy Bodies Consortium. A collaboration with several Parkinson’s Foundation Centers of Excellence and others, the coalition accelerates research to improve diagnosis and treatment of dementia with Lewy bodies, including Parkinson’s disease dementia.

People who experience rapid eye movement (REM) sleep behavior disorder (RBD) are at risk for developing Lewy body dementias. This risk factor might be another potential early diagnosis clue or cue to begin preventative future preventative therapies as they become available.

Learn More

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about PD and dementia by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) or visiting Parkinson’s Foundation resources below.

Podcasts

Episode 67: PD GENE: Genetic Counseling

Many diseases have a genetic component. In most instances, these gene variants are risk factors for the disease, that is, they raise the risk that someone might develop the disease. It is estimated that 10% to 15% of people with Parkinson’s disease (PD) have a genetic form of the disease, and several genes have been identified that may raise the risk of developing PD or may affect its severity and course. Professional genetic counselors can help people sort out their risks, advise them on the pros and cons of getting a genetic test, and explain and put into perspective the results of genetic tests.

The Parkinson’s Foundation has recently initiated the PD GENEration study, which will ultimately recruit and provide genetic testing and counseling to 15,000 people with PD to investigate the relationship between genes and PD. A crucial component of the study is genetic counseling. In this podcast, Certified Genetic Counselor Jenny Verbrugge, MS, CGC of Indiana University, a Parkinson’s Foundation Center of Excellence, discusses the role of genetic counseling in general, in what situations people may want to avail themselves of it, and the value of home genetic tests versus those performed by a clinical laboratory.

Released: November 5, 2019

Podcasts

Episode 10: Young-Onset Parkinson’s 101

A diagnosis of young-onset Parkinson’s disease brings with it special challenges. For example, deciding how and when to disclose the diagnosis at work and to children can be difficult, not to mention coping with a progressive condition and trying to plan for the future. Social worker Elaine Book discusses these challenges and more, as well as techniques for dealing with them.

Key takeaways from Elaine Book:

  • Asking for help is not a sign of weakness; it is a sign of strength.
  • A positive attitude brings positive outcomes.

Released: August 1, 2017

Videos & Webinars

Understanding PD & Mental Health in the Veteran Community

Many veterans with Parkinson’s disease (PD) experience mental health symptoms, like anxiety and depression, that can have a significant impact on quality of life. This webinar explores the relationship between Parkinson’s disease and mental health in the veteran community. Watch to learn how to recognize mental health symptoms, where to go for support and treatment, how to start the conversation with your provider, and for information on the mental health resources and support services that veterans and their care partners have access to through the VA and the Parkinson’s Foundation.

Download Slides

Podcasts

Episode 8: A Vaccine for Parkinson’s?

There are many drugs and therapies for Parkinson’s, but none halt progression of the disease. This is partly because we still do not understand exactly what causes Parkinson’s, so it is hard to figure out how to prevent it or slow it down. One potential target for new therapies is alpha-synuclein, a protein found in the human brain that is associated with the development of PD. Scientists are looking at ways to clear abnormal forms of alpha-synuclein from the brain using various immune therapies. Dr. Mark Guttman discusses these approaches based on what is known and unknown about Parkinson’s today.

Released: August 1, 2017

Podcasts

Episode 132: Managing Comorbidities with Parkinson’s Disease

Just as people in the general population have to contend with various unrelated medical conditions, so may people with Parkinson’s disease (PD). Such conditions are termed “comorbidities,” that is, diseases or conditions occurring along with, in this case, PD. Examples are cardiovascular disease, strokes, arthritis, diabetes, asthma, cancer, cataracts, other diseases of aging, as well as those that can occur at any stage of life. An important consideration is to determine which health professional would be best at addressing them and who coordinates the care.

A movement disorders specialist may feel comfortable treating a general neurological condition in addition to PD, but in this podcast episode, movement disorders neurologist Ashley Rawls, MD, MS of the University of Florida College of Medicine in Gainesville, a Parkinson’s Foundation Center of Excellence, emphasizes that one’s time with her is best used addressing the person’s PD, while comorbidities are most appropriately managed by specialists in those particular areas. For best patient outcomes, proper coordination of care and sharing of information will give each health professional a total picture of the person’s medical management, including prescribed drugs and possible drug interactions.

Released: July 12, 2022

Back to Top